Selected research
Industry Research
C-X-C Chemokine Receptor Type 4 Industry Research Report 2026
Market perspective
The global C-X-C Chemokine Receptor Type 4 market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
North America: the C-X-C Chemokine Receptor Type 4 market is projected to increase from US$ million in 2026 to US$ million by 2032, reflecting a CAGR of % over 2026–2032. Europe: the C-X-C Chemokine Receptor Type 4 market is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032. Asia Pacific: the C-X-C Chemokine Receptor Type 4 market is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032. Leading global service providers of C-X-C Chemokine Receptor Type 4 include Sanofi, Eli Lilly and Company, X4 Pharmaceuticals, Inc., Upsher-Smith Laboratories, Inc., TaiGen Biotechnology Co., Ltd., Polyphor Ltd., Pharis Biotec GmbH, NeED Pharma s.r.l. and GlycoMimetics, Inc., among others; in 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
Read the full market overview
This report quantifies the global C-X-C Chemokine Receptor Type 4 market in terms of revenue (US$ million) and, where applicable, service volume (K Units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region or country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to C-X-C Chemokine Receptor Type 4.
Key Companies & Market Share Insights
This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
C-X-C Chemokine Receptor Type 4 Market by Company
Sanofi
Eli Lilly and Company
X4 Pharmaceuticals, Inc.
Upsher-Smith Laboratories, Inc.
TaiGen Biotechnology Co., Ltd.
Polyphor Ltd.
Pharis Biotec GmbH
NeED Pharma s.r.l.
GlycoMimetics, Inc.
Globavir Biosciences, Inc.
Bristol-Myers Squibb Company
BioLineRx, Ltd.
Biokine Therapeutics Ltd.
Anchor Therapeutics, Inc.
Ambrx, Inc.
AdAlta Pty Ltd.
C-X-C Chemokine Receptor Type 4 Segment by Type
HPH-112
GMI-1359
BL-8040
AM-3114
Others
C-X-C Chemokine Receptor Type 4 Segment by Application
Myocardial Infarction
Renal Cell Carcinoma
Stroke
Liver Cancer
Others
C-X-C Chemokine Receptor Type 4 Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global C-X-C Chemokine Receptor Type 4 market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of C-X-C Chemokine Receptor Type 4 and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of C-X-C Chemokine Receptor Type 4.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of C-X-C Chemokine Receptor Type 4 companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- HPH-112
- GMI-1359
- BL-8040
- AM-3114
- Others
Applications
- Myocardial Infarction
- Renal Cell Carcinoma
- Stroke
- Liver Cancer
- Others
Companies covered
- Sanofi
- Eli Lilly and Company
- X4 Pharmaceuticals, Inc.
- Upsher-Smith Laboratories, Inc.
- TaiGen Biotechnology Co., Ltd.
- Polyphor Ltd.
- Pharis Biotec GmbH
- NeED Pharma s.r.l.
- GlycoMimetics, Inc.
- Globavir Biosciences, Inc.
- Bristol-Myers Squibb Company
- BioLineRx, Ltd.
- Biokine Therapeutics Ltd.
- Anchor Therapeutics, Inc.
- Ambrx, Inc.
- AdAlta Pty Ltd.
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 C-X-C Chemokine Receptor Type 4 by Type
- 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
- 2.2.2 HPH-112
- 2.2.3 GMI-1359
- 2.2.4 BL-8040
- 2.2.5 AM-3114
- 2.2.6 Others
- 2.3 C-X-C Chemokine Receptor Type 4 by Application
- 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.3.2 Myocardial Infarction
- 2.3.3 Renal Cell Carcinoma
- 2.3.4 Stroke
- 2.3.5 Liver Cancer
- 2.3.6 Others
- 2.4 Assumptions and Limitations
3 C-X-C Chemokine Receptor Type 4 Breakdown Data by Type
- 3.1 Global C-X-C Chemokine Receptor Type 4 Historic Market Size by Type (2021-2026)
- 3.2 Global C-X-C Chemokine Receptor Type 4 Forecasted Market Size by Type (2027-2032)
4 C-X-C Chemokine Receptor Type 4 Breakdown Data by Application
- 4.1 Global C-X-C Chemokine Receptor Type 4 Historic Market Size by Application (2021-2026)
- 4.2 Global C-X-C Chemokine Receptor Type 4 Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
- 5.1 Global C-X-C Chemokine Receptor Type 4 Market Perspective (2021-2032)
- 5.2 Global C-X-C Chemokine Receptor Type 4 Growth Trends by Region
- 5.2.1 Global C-X-C Chemokine Receptor Type 4 Market Size by Region: 2021 VS 2025 VS 2032
- 5.2.2 C-X-C Chemokine Receptor Type 4 Historic Market Size by Region (2021-2026)
- 5.2.3 C-X-C Chemokine Receptor Type 4 Forecasted Market Size by Region (2027-2032)
- 5.3 C-X-C Chemokine Receptor Type 4 Market Dynamics
- 5.3.1 C-X-C Chemokine Receptor Type 4 Industry Trends
- 5.3.2 C-X-C Chemokine Receptor Type 4 Market Drivers
- 5.3.3 C-X-C Chemokine Receptor Type 4 Market Challenges
- 5.3.4 C-X-C Chemokine Receptor Type 4 Market Restraints
6 Market Competitive Landscape by Players
- 6.1 Global Top C-X-C Chemokine Receptor Type 4 Players by Revenue
- 6.1.1 Global Top C-X-C Chemokine Receptor Type 4 Players by Revenue (2021-2026)
- 6.1.2 Global C-X-C Chemokine Receptor Type 4 Revenue Market Share by Players (2021-2026)
- 6.2 Global C-X-C Chemokine Receptor Type 4 Industry Players Ranking, 2023 VS 2024 VS 2025
- 6.3 Global Key Players of C-X-C Chemokine Receptor Type 4 Head Office and Area Served
- 6.4 Global C-X-C Chemokine Receptor Type 4 Players, Product Type & Application
- 6.5 Global C-X-C Chemokine Receptor Type 4 Manufacturers Established Date
- 6.6 Global C-X-C Chemokine Receptor Type 4 Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition
7 North America
- 7.1 North America C-X-C Chemokine Receptor Type 4 Market Size (2021-2032)
- 7.2 North America C-X-C Chemokine Receptor Type 4 Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 7.3 North America C-X-C Chemokine Receptor Type 4 Market Size by Country (2021-2026)
- 7.4 North America C-X-C Chemokine Receptor Type 4 Market Size by Country (2027-2032)
- 7.5 United States
- 7.5 United States
- 7.6 Canada
- 7.7 Mexico
8 Europe
- 8.1 Europe C-X-C Chemokine Receptor Type 4 Market Size (2021-2032)
- 8.2 Europe C-X-C Chemokine Receptor Type 4 Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 8.3 Europe C-X-C Chemokine Receptor Type 4 Market Size by Country (2021-2026)
- 8.4 Europe C-X-C Chemokine Receptor Type 4 Market Size by Country (2027-2032)
- 8.5 Germany
- 8.6 France
- 8.7 U.K.
- 8.8 Italy
- 8.9 Spain
- 8.10 Russia
- 8.11 Netherlands
- 8.12 Nordic Countries
9 Asia-Pacific
- 9.1 Asia-Pacific C-X-C Chemokine Receptor Type 4 Market Size (2021-2032)
- 9.2 Asia-Pacific C-X-C Chemokine Receptor Type 4 Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 9.3 Asia-Pacific C-X-C Chemokine Receptor Type 4 Market Size by Country (2021-2026)
- 9.4 Asia-Pacific C-X-C Chemokine Receptor Type 4 Market Size by Country (2027-2032)
- 9.5 China
- 9.6 Japan
- 9.7 South Korea
- 9.8 India
- 9.9 Australia
- 9.10 China Taiwan
- 9.11 Southeast Asia
10 South America
- 10.1 South America C-X-C Chemokine Receptor Type 4 Market Size (2021-2032)
- 10.2 South America C-X-C Chemokine Receptor Type 4 Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 10.3 South America C-X-C Chemokine Receptor Type 4 Market Size by Country (2021-2026)
- 10.4 South America C-X-C Chemokine Receptor Type 4 Market Size by Country (2027-2032)
- 10.5 Brazil
- 10.6 Argentina
- 10.7 Chile
- 10.8 Colombia
- 10.9 Peru
11 Middle East & Africa
- 11.1 Middle East & Africa C-X-C Chemokine Receptor Type 4 Market Size (2021-2032)
- 11.2 Middle East & Africa C-X-C Chemokine Receptor Type 4 Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 11.3 Middle East & Africa C-X-C Chemokine Receptor Type 4 Market Size by Country (2021-2026)
- 11.4 Middle East & Africa C-X-C Chemokine Receptor Type 4 Market Size by Country (2027-2032)
- 11.5 Saudi Arabia
- 11.6 Israel
- 11.7 United Arab Emirates
- 11.8 Turkey
- 11.9 Iran
- 11.10 Egypt
12 Players Profiled
- 12.1 Sanofi
- 12.1.1 Sanofi Company Information
- 12.1.2 Sanofi Business Overview
- 12.1.3 Sanofi Revenue in C-X-C Chemokine Receptor Type 4 Business (2021-2026)
- 12.1.4 Sanofi C-X-C Chemokine Receptor Type 4 Product Portfolio
- 12.1.5 Sanofi Recent Developments
- 12.2 Eli Lilly and Company
- 12.2.1 Eli Lilly and Company Company Information
- 12.2.2 Eli Lilly and Company Business Overview
- 12.2.3 Eli Lilly and Company Revenue in C-X-C Chemokine Receptor Type 4 Business (2021-2026)
- 12.2.4 Eli Lilly and Company C-X-C Chemokine Receptor Type 4 Product Portfolio
- 12.2.5 Eli Lilly and Company Recent Developments
- 12.3 X4 Pharmaceuticals, Inc.
- 12.3.1 X4 Pharmaceuticals, Inc. Company Information
- 12.3.2 X4 Pharmaceuticals, Inc. Business Overview
- 12.3.3 X4 Pharmaceuticals, Inc. Revenue in C-X-C Chemokine Receptor Type 4 Business (2021-2026)
- 12.3.4 X4 Pharmaceuticals, Inc. C-X-C Chemokine Receptor Type 4 Product Portfolio
- 12.3.5 X4 Pharmaceuticals, Inc. Recent Developments
- 12.4 Upsher-Smith Laboratories, Inc.
- 12.4.1 Upsher-Smith Laboratories, Inc. Company Information
- 12.4.2 Upsher-Smith Laboratories, Inc. Business Overview
- 12.4.3 Upsher-Smith Laboratories, Inc. Revenue in C-X-C Chemokine Receptor Type 4 Business (2021-2026)
- 12.4.4 Upsher-Smith Laboratories, Inc. C-X-C Chemokine Receptor Type 4 Product Portfolio
- 12.4.5 Upsher-Smith Laboratories, Inc. Recent Developments
- 12.5 TaiGen Biotechnology Co., Ltd.
- 12.5.1 TaiGen Biotechnology Co., Ltd. Company Information
- 12.5.2 TaiGen Biotechnology Co., Ltd. Business Overview
- 12.5.3 TaiGen Biotechnology Co., Ltd. Revenue in C-X-C Chemokine Receptor Type 4 Business (2021-2026)
- 12.5.4 TaiGen Biotechnology Co., Ltd. C-X-C Chemokine Receptor Type 4 Product Portfolio
- 12.5.5 TaiGen Biotechnology Co., Ltd. Recent Developments
- 12.6 Polyphor Ltd.
- 12.6.1 Polyphor Ltd. Company Information
- 12.6.2 Polyphor Ltd. Business Overview
- 12.6.3 Polyphor Ltd. Revenue in C-X-C Chemokine Receptor Type 4 Business (2021-2026)
- 12.6.4 Polyphor Ltd. C-X-C Chemokine Receptor Type 4 Product Portfolio
- 12.6.5 Polyphor Ltd. Recent Developments
- 12.7 Pharis Biotec GmbH
- 12.7.1 Pharis Biotec GmbH Company Information
- 12.7.2 Pharis Biotec GmbH Business Overview
- 12.7.3 Pharis Biotec GmbH Revenue in C-X-C Chemokine Receptor Type 4 Business (2021-2026)
- 12.7.4 Pharis Biotec GmbH C-X-C Chemokine Receptor Type 4 Product Portfolio
- 12.7.5 Pharis Biotec GmbH Recent Developments
- 12.8 NeED Pharma s.r.l.
- 12.8.1 NeED Pharma s.r.l. Company Information
- 12.8.2 NeED Pharma s.r.l. Business Overview
- 12.8.3 NeED Pharma s.r.l. Revenue in C-X-C Chemokine Receptor Type 4 Business (2021-2026)
- 12.8.4 NeED Pharma s.r.l. C-X-C Chemokine Receptor Type 4 Product Portfolio
- 12.8.5 NeED Pharma s.r.l. Recent Developments
- 12.9 GlycoMimetics, Inc.
- 12.9.1 GlycoMimetics, Inc. Company Information
- 12.9.2 GlycoMimetics, Inc. Business Overview
- 12.9.3 GlycoMimetics, Inc. Revenue in C-X-C Chemokine Receptor Type 4 Business (2021-2026)
- 12.9.4 GlycoMimetics, Inc. C-X-C Chemokine Receptor Type 4 Product Portfolio
- 12.9.5 GlycoMimetics, Inc. Recent Developments
- 12.10 Globavir Biosciences, Inc.
- 12.10.1 Globavir Biosciences, Inc. Company Information
- 12.10.2 Globavir Biosciences, Inc. Business Overview
- 12.10.3 Globavir Biosciences, Inc. Revenue in C-X-C Chemokine Receptor Type 4 Business (2021-2026)
- 12.10.4 Globavir Biosciences, Inc. C-X-C Chemokine Receptor Type 4 Product Portfolio
- 12.10.5 Globavir Biosciences, Inc. Recent Developments
- 12.11 Bristol-Myers Squibb Company
- 12.11.1 Bristol-Myers Squibb Company Company Information
- 12.11.2 Bristol-Myers Squibb Company Business Overview
- 12.11.3 Bristol-Myers Squibb Company Revenue in C-X-C Chemokine Receptor Type 4 Business (2021-2026)
- 12.11.4 Bristol-Myers Squibb Company C-X-C Chemokine Receptor Type 4 Product Portfolio
- 12.11.5 Bristol-Myers Squibb Company Recent Developments
- 12.12 BioLineRx, Ltd.
- 12.12.1 BioLineRx, Ltd. Company Information
- 12.12.2 BioLineRx, Ltd. Business Overview
- 12.12.3 BioLineRx, Ltd. Revenue in C-X-C Chemokine Receptor Type 4 Business (2021-2026)
- 12.12.4 BioLineRx, Ltd. C-X-C Chemokine Receptor Type 4 Product Portfolio
- 12.12.5 BioLineRx, Ltd. Recent Developments
- 12.13 Biokine Therapeutics Ltd.
- 12.13.1 Biokine Therapeutics Ltd. Company Information
- 12.13.2 Biokine Therapeutics Ltd. Business Overview
- 12.13.3 Biokine Therapeutics Ltd. Revenue in C-X-C Chemokine Receptor Type 4 Business (2021-2026)
- 12.13.4 Biokine Therapeutics Ltd. C-X-C Chemokine Receptor Type 4 Product Portfolio
- 12.13.5 Biokine Therapeutics Ltd. Recent Developments
- 12.14 Anchor Therapeutics, Inc.
- 12.14.1 Anchor Therapeutics, Inc. Company Information
- 12.14.2 Anchor Therapeutics, Inc. Business Overview
- 12.14.3 Anchor Therapeutics, Inc. Revenue in C-X-C Chemokine Receptor Type 4 Business (2021-2026)
- 12.14.4 Anchor Therapeutics, Inc. C-X-C Chemokine Receptor Type 4 Product Portfolio
- 12.14.5 Anchor Therapeutics, Inc. Recent Developments
- 12.15 Ambrx, Inc.
- 12.15.1 Ambrx, Inc. Company Information
- 12.15.2 Ambrx, Inc. Business Overview
- 12.15.3 Ambrx, Inc. Revenue in C-X-C Chemokine Receptor Type 4 Business (2021-2026)
- 12.15.4 Ambrx, Inc. C-X-C Chemokine Receptor Type 4 Product Portfolio
- 12.15.5 Ambrx, Inc. Recent Developments
- 12.16 AdAlta Pty Ltd.
- 12.16.1 AdAlta Pty Ltd. Company Information
- 12.16.2 AdAlta Pty Ltd. Business Overview
- 12.16.3 AdAlta Pty Ltd. Revenue in C-X-C Chemokine Receptor Type 4 Business (2021-2026)
- 12.16.4 AdAlta Pty Ltd. C-X-C Chemokine Receptor Type 4 Product Portfolio
- 12.16.5 AdAlta Pty Ltd. Recent Developments
13 Report Conclusion
14 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst